Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial

Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial

Abstract Ataxia telangiectasia and Rad3-related kinase (ATR) is a rational radiosensitization target. In this study, we explore the combination of the ATR inhibitor, ceralasertib, and palliative radiotherapy, with primary endpoint the identification of maximum tolerated dose, and secondary endpoints...

Full description

Saved in:
Bibliographic Details
Main Authors: Magnus T. Dillon, Emmanuel C. Patin, Kabir Mohammed, Jeane Guevara, Simon A. Smith, Emma Dean, Heba Soliman, Pablo Nenclares, Motoko Ryugenji, Davina Northcote, Neel Shah, Lorna Grove, Christopher J. Lord, Stephen Pettit, Matt Tall, Karen E. Swales, Udai Banerji, Alan A. Melcher, Mark Saunders, Martin D. Forster, Kevin J. Harrington
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-62249-0
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items